AB Ility

Ab-ility is a German biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company utilizes a proprietary platform focused on generating high-affinity antibodies, particularly leveraging rabbit-derived immune repertoires which are known for superior diversity and binding characteristics. Ab-ility provides antibody engineering services and develops its own internal pipeline of candidates for oncology and inflammatory indications. The firm is closely associated with the expertise of the former MAB Discovery team, emphasizing high-throughput screening and sophisticated B-cell cloning techniques.